Champions Oncology (CSBR) Current Deferred Revenue (2011 - 2026)

Champions Oncology (CSBR) has 16 years of Current Deferred Revenue data on file, last reported at $9.6 million in Q3 2026.

• On a quarterly basis, Current Deferred Revenue fell 33.8% year-over-year to $9.6 million in Q3 2026; TTM through Jul 2026 was $9.6 million, a 33.8% decrease from a year earlier, with the FY2026 full-year figure at $8.8 million, down 42.83% from the prior year.
• Current Deferred Revenue for Q3 2026 stood at $9.6 million, up from $8.8 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $15.4 million in Q2 2025 and bottomed at $8.7 million in Q1 2022.
• Historically, Current Deferred Revenue has averaged $11.5 million across 5 years, with a median of $11.1 million in 2022.
• The widest annual swing landed in 2022, when Current Deferred Revenue surged 98.87%; it then tumbled 42.83% in 2026.
• Year by year, Current Deferred Revenue stood at $11.2 million in 2022, then climbed by 16.07% to $13.0 million in 2023, then fell by 21.38% to $10.2 million in 2024, then grew by 20.72% to $12.3 million in 2025, then declined by 22.58% to $9.6 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $9.6 million in Q3 2026, $8.8 million in Q2 2026, and $10.0 million in Q1 2026.